| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.
|
AIDS
|
2002
|
2.28
|
|
2
|
Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.
|
Ann Intern Med
|
2003
|
2.20
|
|
3
|
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results].
|
Enferm Infecc Microbiol Clin
|
2007
|
1.83
|
|
4
|
Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
|
Clin Pharmacokinet
|
2002
|
1.75
|
|
5
|
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].
|
Enferm Infecc Microbiol Clin
|
2004
|
1.42
|
|
6
|
The changing etiology of fever of intermediate duration.
|
Enferm Infecc Microbiol Clin
|
2010
|
1.40
|
|
7
|
The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.
|
Clin Infect Dis
|
2007
|
1.39
|
|
8
|
Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
|
PLoS One
|
2006
|
1.32
|
|
9
|
Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality.
|
Curr HIV Res
|
2009
|
1.30
|
|
10
|
Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
|
AIDS Res Hum Retroviruses
|
2006
|
1.26
|
|
11
|
Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy.
|
Curr HIV Res
|
2008
|
1.17
|
|
12
|
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
|
J Antimicrob Chemother
|
2008
|
1.14
|
|
13
|
Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy.
|
AIDS
|
2012
|
1.09
|
|
14
|
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
|
J Antimicrob Chemother
|
2008
|
1.05
|
|
15
|
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
|
Antivir Ther
|
2004
|
1.01
|
|
16
|
Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort.
|
J Womens Health (Larchmt)
|
2007
|
1.01
|
|
17
|
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
|
AIDS
|
2004
|
1.00
|
|
18
|
[Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people].
|
Enferm Infecc Microbiol Clin
|
2009
|
0.98
|
|
19
|
Hepatitis C virus and human immunodeficiency virus coinfection in Spain.
|
J Infect
|
2003
|
0.96
|
|
20
|
Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers.
|
J Virol
|
2012
|
0.95
|
|
21
|
Q fever: epidemiology, clinical features and prognosis. A study from 1983 to 1999 in the South of Spain.
|
J Infect
|
2003
|
0.94
|
|
22
|
Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level viremia.
|
J Acquir Immune Defic Syndr
|
2011
|
0.92
|
|
23
|
Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care.
|
Antivir Ther
|
2012
|
0.91
|
|
24
|
Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences.
|
AIDS Patient Care STDS
|
2005
|
0.90
|
|
25
|
Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2003
|
0.90
|
|
26
|
HIV infection-related premature immunosenescence: high rates of immune exhaustion after short time of infection.
|
Curr HIV Res
|
2011
|
0.89
|
|
27
|
Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine.
|
J Infect Dis
|
2010
|
0.88
|
|
28
|
What drives the number of high-risk human papillomavirus types in the anal canal in HIV-positive men who have sex with men?
|
J Infect Dis
|
2013
|
0.87
|
|
29
|
Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
|
Ann Intern Med
|
2009
|
0.86
|
|
30
|
Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART.
|
Curr HIV Res
|
2009
|
0.86
|
|
31
|
Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.
|
AIDS
|
2014
|
0.86
|
|
32
|
Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.
|
J Antimicrob Chemother
|
2008
|
0.86
|
|
33
|
Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.
|
Ther Drug Monit
|
2007
|
0.85
|
|
34
|
Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort).
|
AIDS
|
2002
|
0.85
|
|
35
|
Anal squamous intraepithelial lesions are frequent among young HIV-infected men who have sex with men followed up at the Spanish AIDS Research Network Cohort (CoRIS-HPV).
|
Int J Cancer
|
2013
|
0.84
|
|
36
|
Rate and predictors of progression in elite and viremic HIV-1 controllers.
|
AIDS
|
2016
|
0.83
|
|
37
|
Mitochondrial haplogroups are associated with clinical pattern of AIDS progression in HIV-infected patients.
|
J Acquir Immune Defic Syndr
|
2013
|
0.83
|
|
38
|
Anal human papillomavirus genotype distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort.
|
J Clin Microbiol
|
2013
|
0.83
|
|
39
|
Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors.
|
AIDS
|
2016
|
0.82
|
|
40
|
Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.
|
BMC Womens Health
|
2011
|
0.82
|
|
41
|
High levels of CD57+CD28- T-cells, low T-cell proliferation and preferential expansion of terminally differentiated CD4+ T-cells in HIV-elite controllers.
|
Curr HIV Res
|
2010
|
0.81
|
|
42
|
Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain.
|
BMC Infect Dis
|
2010
|
0.80
|
|
43
|
Molecular epidemiology of HIV type 1 in newly diagnosed patients in southern Spain.
|
AIDS Res Hum Retroviruses
|
2008
|
0.80
|
|
44
|
Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.
|
Antivir Ther
|
2014
|
0.80
|
|
45
|
Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.
|
Medicine (Baltimore)
|
2015
|
0.79
|
|
46
|
Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.
|
PLoS One
|
2012
|
0.79
|
|
47
|
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
|
Retrovirology
|
2012
|
0.79
|
|
48
|
ACSM4 polymorphisms are associated with rapid AIDS progression in HIV-infected patients.
|
J Acquir Immune Defic Syndr
|
2014
|
0.79
|
|
49
|
Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
|
Clin Infect Dis
|
2013
|
0.79
|
|
50
|
Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
|
Antimicrob Agents Chemother
|
2007
|
0.79
|
|
51
|
[Reasons for antiretroviral treatment change in HIV+ patients in Spain in 2010-2011. SWITCH AUDIT Study].
|
Rev Esp Quimioter
|
2014
|
0.78
|
|
52
|
IL28B single-nucleotide polymorphism rs12979860 is associated with spontaneous HIV control in white subjects.
|
J Infect Dis
|
2012
|
0.78
|
|
53
|
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
|
J Antimicrob Chemother
|
2008
|
0.78
|
|
54
|
Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010.
|
Virol J
|
2011
|
0.77
|
|
55
|
[Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002].
|
Enferm Infecc Microbiol Clin
|
2002
|
0.76
|
|
56
|
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study.
|
Curr HIV Res
|
2012
|
0.76
|
|
57
|
Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.
|
AIDS Res Ther
|
2010
|
0.75
|
|
58
|
Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
|
Medicine (Baltimore)
|
2015
|
0.75
|
|
59
|
Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.
|
Antimicrob Agents Chemother
|
2013
|
0.75
|
|
60
|
[Changing trends in HIV epidemics: recent diagnoses in the Spanish VACH cohort (2000-2002)].
|
Enferm Infecc Microbiol Clin
|
2005
|
0.75
|
|
61
|
[Spanish recommendations for proper use of enfuvirtide].
|
Enferm Infecc Microbiol Clin
|
2007
|
0.75
|
|
62
|
[Immunological, virological and clinical response in patients infected with HIV after highly active antiviral therapy with nelfinavir: prospective cohort study].
|
Enferm Infecc Microbiol Clin
|
2003
|
0.75
|
|
63
|
Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort.
|
Enferm Infecc Microbiol Clin
|
2010
|
0.75
|
|
64
|
Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
|
J Antimicrob Chemother
|
2017
|
0.75
|
|
65
|
Virological and immunological stability in HIV infected patients undergoing partial-treatment interruption.
|
J Clin Virol
|
2009
|
0.75
|
|
66
|
[Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection].
|
Enferm Infecc Microbiol Clin
|
2006
|
0.75
|